ID   HTRA2_HUMAN             Reviewed;         458 AA.
AC   O43464; Q9HBZ4; Q9P0Y3; Q9P0Y4;
DT   26-SEP-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 2.
DT   28-JAN-2026, entry version 241.
DE   RecName: Full=Serine protease HTRA2, mitochondrial;
DE            EC=3.4.21.108;
DE   AltName: Full=High temperature requirement protein A2;
DE            Short=HtrA2;
DE   AltName: Full=Omi stress-regulated endoprotease;
DE   AltName: Full=Serine protease 25;
DE   AltName: Full=Serine proteinase OMI;
DE   Flags: Precursor;
GN   Name=HTRA2; Synonyms=OMI, PRSS25;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND MUTAGENESIS OF SER-306.
RX   PubMed=10644717; DOI=10.1074/jbc.275.4.2581;
RA   Faccio L., Fusco C., Chen A., Martinotti S., Bonventre J.V., Zervos A.S.;
RT   "Characterization of a novel human serine protease that has extensive
RT   homology to bacterial heat shock endoprotease HtrA and is regulated by
RT   kidney ischemia.";
RL   J. Biol. Chem. 275:2581-2588(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 3 AND 4), AND CHARACTERIZATION.
RC   TISSUE=Brain;
RX   PubMed=10971580; DOI=10.1046/j.1432-1327.2000.01589.x;
RA   Gray C.W., Ward R.V., Karran E.H., Turconi S., Rowles A., Viglienghi D.,
RA   Southan C., Barton A., Fantom K.G., West A., Savopoulos J.W., Hassan N.J.,
RA   Clinkenbeard H., Hanning C., Amegadzie B., Davis J.B., Dingwall C.,
RA   Livi G.P., Creasy C.L.;
RT   "Characterization of human HtrA2, a novel serine protease involved in the
RT   mammalian cellular stress response.";
RL   Eur. J. Biochem. 267:5699-5710(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Kidney;
RX   PubMed=10995577; DOI=10.1006/geno.2000.6263;
RA   Faccio L., Fusco C., Viel A., Zervos A.S.;
RT   "Tissue-specific splicing of Omi stress-regulated endoprotease leads to an
RT   inactive protease with a modified PDZ motif.";
RL   Genomics 68:343-347(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 134-458, INTERACTION WITH XIAP, AND MUTAGENESIS OF
RP   ALA-134.
RX   PubMed=11583623; DOI=10.1016/s1097-2765(01)00341-0;
RA   Suzuki Y., Imai Y., Nakayama H., Takahashi K., Takio K., Takahashi R.;
RT   "A serine protease, HtrA2, is released from the mitochondria and interacts
RT   with XIAP, inducing cell death.";
RL   Mol. Cell 8:613-621(2001).
RN   [7]
RP   CHARACTERIZATION, AND PHOSPHORYLATION.
RX   PubMed=10873535; DOI=10.1006/prep.2000.1240;
RA   Savopoulos J.W., Carter P.S., Turconi S., Pettman G.R., Karran E.H.,
RA   Gray C.W., Ward R.V., Jenkins O., Creasy C.L.;
RT   "Expression, purification, and functional analysis of the human serine
RT   protease HtrA2.";
RL   Protein Expr. Purif. 19:227-234(2000).
RN   [8]
RP   FUNCTION, AND INTERACTION WITH BIRC6/BRUCE.
RX   PubMed=15200957; DOI=10.1016/j.molcel.2004.05.018;
RA   Bartke T., Pohl C., Pyrowolakis G., Jentsch S.;
RT   "Dual role of BRUCE as an antiapoptotic IAP and a chimeric E2/E3 ubiquitin
RT   ligase.";
RL   Mol. Cell 14:801-811(2004).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH THAP5.
RX   PubMed=19502560; DOI=10.1152/ajpheart.00234.2009;
RA   Balakrishnan M.P., Cilenti L., Mashak Z., Popat P., Alnemri E.S.,
RA   Zervos A.S.;
RT   "THAP5 is a human cardiac-specific inhibitor of cell cycle that is cleaved
RT   by the proapoptotic Omi/HtrA2 protease during cell death.";
RL   Am. J. Physiol. 297:H643-H653(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   INTERACTION WITH AREL1.
RX   PubMed=23479728; DOI=10.1074/jbc.m112.436113;
RA   Kim J.B., Kim S.Y., Kim B.M., Lee H., Kim I., Yun J., Jo Y., Oh T., Jo Y.,
RA   Chae H.D., Shin D.Y.;
RT   "Identification of a novel anti-apoptotic E3 ubiquitin ligase that
RT   ubiquitinates antagonists of inhibitor of apoptosis proteins SMAC, HtrA2,
RT   and ARTS.";
RL   J. Biol. Chem. 288:12014-12021(2013).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [14] {ECO:0007744|PDB:1LCY}
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 134-458, SUBUNIT, AND ACTIVE SITE.
RX   PubMed=11967569; DOI=10.1038/nsb795;
RA   Li W., Srinivasula S.M., Chai J., Li P., Wu J.W., Zhang Z., Alnemri E.S.,
RA   Shi Y.;
RT   "Structural insights into the pro-apoptotic function of mitochondrial
RT   serine protease HtrA2/Omi.";
RL   Nat. Struct. Biol. 9:436-441(2002).
RN   [15] {ECO:0007744|PDB:8E2K}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.21 ANGSTROMS) OF 134-458 IN COMPLEX
RP   WITH BIRC6, FUNCTION, ACTIVITY REGULATION, SUBUNIT, AND UBIQUITINATION BY
RP   BIRC6.
RX   PubMed=36758104; DOI=10.1126/science.ade5750;
RA   Hunkeler M., Jin C.Y., Fischer E.S.;
RT   "Structures of BIRC6-client complexes provide a mechanism of SMAC-mediated
RT   release of caspases.";
RL   Science 379:1105-1111(2023).
RN   [16] {ECO:0007744|PDB:8AUK}
RP   STRUCTURE BY ELECTRON MICROSCOPY (6.20 ANGSTROMS) OF 134-458 IN COMPLEX
RP   WITH BIRC6, FUNCTION, ACTIVITY REGULATION, SUBUNIT, AND UBIQUITINATION BY
RP   BIRC6.
RX   PubMed=36758105; DOI=10.1126/science.ade8873;
RA   Ehrmann J.F., Grabarczyk D.B., Heinke M., Deszcz L., Kurzbauer R.,
RA   Hudecz O., Shulkina A., Gogova R., Meinhart A., Versteeg G.A., Clausen T.;
RT   "Structural basis for regulation of apoptosis and autophagy by the
RT   BIRC6/SMAC complex.";
RL   Science 379:1117-1123(2023).
RN   [17]
RP   INVOLVEMENT IN PARK13, VARIANTS SER-141 AND SER-399, AND CHARACTERIZATION
RP   OF VARIANTS SER-141 AND SER-399.
RX   PubMed=15961413; DOI=10.1093/hmg/ddi215;
RA   Strauss K.M., Martins L.M., Plun-Favreau H., Marx F.P., Kautzmann S.,
RA   Berg D., Gasser T., Wszolek Z., Mueller T., Bornemann A., Wolburg H.,
RA   Downward J., Riess O., Schulz J.B., Krueger R.;
RT   "Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's
RT   disease.";
RL   Hum. Mol. Genet. 14:2099-2111(2005).
RN   [18]
RP   INVOLVEMENT IN PARK13, VARIANTS PRO-72 AND SER-141, AND VARIANT PARK13
RP   TRP-404.
RX   PubMed=18401856; DOI=10.1002/humu.20713;
RA   Bogaerts V., Nuytemans K., Reumers J., Pals P., Engelborghs S., Pickut B.,
RA   Corsmit E., Peeters K., Schymkowitz J., De Deyn P.P., Cras P., Rousseau F.,
RA   Theuns J., Van Broeckhoven C.;
RT   "Genetic variability in the mitochondrial serine protease HTRA2 contributes
RT   to risk for Parkinson disease.";
RL   Hum. Mutat. 29:832-840(2008).
RN   [19]
RP   VARIANTS CYS-12; LEU-128; SER-141; SER-227 AND SER-399.
RX   PubMed=18364387; DOI=10.1093/hmg/ddn096;
RA   Simon-Sanchez J., Singleton A.B.;
RT   "Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic
RT   mutations in neurologically normal controls.";
RL   Hum. Mol. Genet. 17:1988-1993(2008).
RN   [20]
RP   VARIANT SER-399.
RX   PubMed=25422467; DOI=10.1073/pnas.1419581111;
RA   Unal Gulsuner H., Gulsuner S., Mercan F.N., Onat O.E., Walsh T., Shahin H.,
RA   Lee M.K., Dogu O., Kansu T., Topaloglu H., Elibol B., Akbostanci C.,
RA   King M.C., Ozcelik T., Tekinay A.B.;
RT   "Mitochondrial serine protease HTRA2 p.G399S in a kindred with essential
RT   tremor and Parkinson disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:18285-18290(2014).
RN   [21]
RP   INVOLVEMENT IN MGCA8, VARIANT MGCA8 GLN-404, AND CHARACTERIZATION OF
RP   VARIANT MGCA8 GLN-404.
RX   PubMed=27208207; DOI=10.1136/jmedgenet-2016-103922;
RA   Mandel H., Saita S., Edvardson S., Jalas C., Shaag A., Goldsher D.,
RA   Vlodavsky E., Langer T., Elpeleg O.;
RT   "Deficiency of HTRA2/Omi is associated with infantile neurodegeneration and
RT   3-methylglutaconic aciduria.";
RL   J. Med. Genet. 53:690-696(2016).
RN   [22]
RP   VARIANT SER-399.
RX   PubMed=27535533; DOI=10.1038/nature19057;
RG   Exome Aggregation Consortium;
RA   Lek M., Karczewski K.J., Minikel E.V., Samocha K.E., Banks E., Fennell T.,
RA   O'Donnell-Luria A.H., Ware J.S., Hill A.J., Cummings B.B., Tukiainen T.,
RA   Birnbaum D.P., Kosmicki J.A., Duncan L.E., Estrada K., Zhao F., Zou J.,
RA   Pierce-Hoffman E., Berghout J., Cooper D.N., Deflaux N., DePristo M.,
RA   Do R., Flannick J., Fromer M., Gauthier L., Goldstein J., Gupta N.,
RA   Howrigan D., Kiezun A., Kurki M.I., Moonshine A.L., Natarajan P.,
RA   Orozco L., Peloso G.M., Poplin R., Rivas M.A., Ruano-Rubio V., Rose S.A.,
RA   Ruderfer D.M., Shakir K., Stenson P.D., Stevens C., Thomas B.P., Tiao G.,
RA   Tusie-Luna M.T., Weisburd B., Won H.H., Yu D., Altshuler D.M.,
RA   Ardissino D., Boehnke M., Danesh J., Donnelly S., Elosua R., Florez J.C.,
RA   Gabriel S.B., Getz G., Glatt S.J., Hultman C.M., Kathiresan S., Laakso M.,
RA   McCarroll S., McCarthy M.I., McGovern D., McPherson R., Neale B.M.,
RA   Palotie A., Purcell S.M., Saleheen D., Scharf J.M., Sklar P.,
RA   Sullivan P.F., Tuomilehto J., Tsuang M.T., Watkins H.C., Wilson J.G.,
RA   Daly M.J., MacArthur D.G.;
RT   "Analysis of protein-coding genetic variation in 60,706 humans.";
RL   Nature 536:285-291(2016).
RN   [23]
RP   VARIANT MGCA8 243-LEU-PRO-244 DELINS PRO-SER, AND CHARACTERIZATION OF
RP   VARIANT MGCA8 243-LEU-PRO-244 DELINS PRO-SER.
RX   PubMed=27696117; DOI=10.1007/s10545-016-9977-2;
RA   Olahova M., Thompson K., Hardy S.A., Barbosa I.A., Besse A.,
RA   Anagnostou M.E., White K., Davey T., Simpson M.A., Champion M., Enns G.,
RA   Schelley S., Lightowlers R.N., Chrzanowska-Lightowlers Z.M., McFarland R.,
RA   Deshpande C., Bonnen P.E., Taylor R.W.;
RT   "Pathogenic variants in HTRA2 cause an early-onset mitochondrial syndrome
RT   associated with 3-methylglutaconic aciduria.";
RL   J. Inherit. Metab. Dis. 40:121-130(2017).
CC   -!- FUNCTION: [Isoform 1]: Serine protease that shows proteolytic activity
CC       against a non-specific substrate beta-casein (PubMed:10873535).
CC       Promotes apoptosis by either relieving the inhibition of BIRC proteins
CC       on caspases, leading to an increase in caspase activity; or by a BIRC
CC       inhibition-independent, caspase-independent and serine protease
CC       activity-dependent mechanism (PubMed:15200957). Cleaves BIRC6 and
CC       relieves its inhibition on CASP3, CASP7 and CASP9, but it is also prone
CC       to inhibition by BIRC6 (PubMed:36758104, PubMed:36758105). Cleaves
CC       THAP5 and promotes its degradation during apoptosis (PubMed:19502560).
CC       {ECO:0000269|PubMed:10873535, ECO:0000269|PubMed:15200957,
CC       ECO:0000269|PubMed:19502560, ECO:0000269|PubMed:36758104,
CC       ECO:0000269|PubMed:36758105}.
CC   -!- FUNCTION: [Isoform 2]: Seems to be proteolytically inactive.
CC       {ECO:0000269|PubMed:10995577}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Cleavage of non-polar aliphatic amino-acids at the P1
CC         position, with a preference for Val, Ile and Met. At the P2 and P3
CC         positions, Arg is selected most strongly with a secondary preference
CC         for other hydrophilic residues.; EC=3.4.21.108;
CC   -!- ACTIVITY REGULATION: Inhibited by BIRC6. {ECO:0000269|PubMed:36758104,
CC       ECO:0000269|PubMed:36758105}.
CC   -!- SUBUNIT: Homotrimer (PubMed:36758104, PubMed:36758105). Interacts with
CC       MXI2. Interacts with THAP5 under apoptotic conditions. The mature
CC       protein, but not the precursor, binds to BIRC2/c-IAP1, BIRC3/c-IAP2 and
CC       XIAP/BIRC4. Interacts with AREL1 (via HECT domain); in the cytoplasm
CC       following induction of apoptosis (PubMed:23479728).
CC       {ECO:0000269|PubMed:11583623, ECO:0000269|PubMed:11967569,
CC       ECO:0000269|PubMed:15200957, ECO:0000269|PubMed:19502560,
CC       ECO:0000269|PubMed:23479728}.
CC   -!- INTERACTION:
CC       O43464; Q6ZTN6-2: ANKRD13D; NbExp=3; IntAct=EBI-517086, EBI-25840993;
CC       O43464; Q8IUR7: ARMC8; NbExp=6; IntAct=EBI-517086, EBI-1049469;
CC       O43464; Q86TN1: ARNT2; NbExp=3; IntAct=EBI-517086, EBI-25844820;
CC       O43464; Q9Y575-3: ASB3; NbExp=3; IntAct=EBI-517086, EBI-14199987;
CC       O43464; Q96DX5-3: ASB9; NbExp=3; IntAct=EBI-517086, EBI-25843552;
CC       O43464; Q96FT7-4: ASIC4; NbExp=3; IntAct=EBI-517086, EBI-9089489;
CC       O43464; Q13490: BIRC2; NbExp=4; IntAct=EBI-517086, EBI-514538;
CC       O43464; Q96CA5: BIRC7; NbExp=5; IntAct=EBI-517086, EBI-517623;
CC       O43464; Q7Z7K6: CENPV; NbExp=3; IntAct=EBI-517086, EBI-1210604;
CC       O43464; P02489: CRYAA; NbExp=3; IntAct=EBI-517086, EBI-6875961;
CC       O43464; Q5TAQ9-2: DCAF8; NbExp=3; IntAct=EBI-517086, EBI-25842815;
CC       O43464; O00303: EIF3F; NbExp=3; IntAct=EBI-517086, EBI-711990;
CC       O43464; Q8TC29: ENKUR; NbExp=3; IntAct=EBI-517086, EBI-9246952;
CC       O43464; Q13216-2: ERCC8; NbExp=3; IntAct=EBI-517086, EBI-16466949;
CC       O43464; Q99871: HAUS7; NbExp=3; IntAct=EBI-517086, EBI-395719;
CC       O43464; Q02363: ID2; NbExp=3; IntAct=EBI-517086, EBI-713450;
CC       O43464; Q8IY31-2: IFT20; NbExp=3; IntAct=EBI-517086, EBI-11742277;
CC       O43464; Q8N5Z5: KCTD17; NbExp=3; IntAct=EBI-517086, EBI-743960;
CC       O43464; Q6P597: KLC3; NbExp=3; IntAct=EBI-517086, EBI-1643885;
CC       O43464; P57682: KLF3; NbExp=3; IntAct=EBI-517086, EBI-8472267;
CC       O43464; Q9Y2M5: KLHL20; NbExp=3; IntAct=EBI-517086, EBI-714379;
CC       O43464; P08727: KRT19; NbExp=3; IntAct=EBI-517086, EBI-742756;
CC       O43464; Q14525: KRT33B; NbExp=3; IntAct=EBI-517086, EBI-1049638;
CC       O43464; Q1L5Z9: LONRF2; NbExp=3; IntAct=EBI-517086, EBI-2510853;
CC       O43464; Q99683: MAP3K5; NbExp=3; IntAct=EBI-517086, EBI-476263;
CC       O43464; Q8NA82: MARCHF10; NbExp=3; IntAct=EBI-517086, EBI-2341554;
CC       O43464; Q8N594: MPND; NbExp=3; IntAct=EBI-517086, EBI-2512452;
CC       O43464; Q8WY64: MYLIP; NbExp=3; IntAct=EBI-517086, EBI-6952711;
CC       O43464; Q9P0J0: NDUFA13; NbExp=8; IntAct=EBI-517086, EBI-372742;
CC       O43464; Q13562: NEUROD1; NbExp=3; IntAct=EBI-517086, EBI-3908303;
CC       O43464; O15381-5: NVL; NbExp=3; IntAct=EBI-517086, EBI-18577082;
CC       O43464; Q96FW1: OTUB1; NbExp=3; IntAct=EBI-517086, EBI-1058491;
CC       O43464; Q6GQQ9-2: OTUD7B; NbExp=3; IntAct=EBI-517086, EBI-25830200;
CC       O43464; Q9NUU6: OTULINL; NbExp=3; IntAct=EBI-517086, EBI-6916492;
CC       O43464; Q9HBE1-4: PATZ1; NbExp=3; IntAct=EBI-517086, EBI-11022007;
CC       O43464; Q9NV79: PCMTD2; NbExp=3; IntAct=EBI-517086, EBI-6309018;
CC       O43464; O14813: PHOX2A; NbExp=3; IntAct=EBI-517086, EBI-25844430;
CC       O43464; O75925: PIAS1; NbExp=3; IntAct=EBI-517086, EBI-629434;
CC       O43464; Q8WWB5: PIH1D2; NbExp=3; IntAct=EBI-517086, EBI-10232538;
CC       O43464; Q96T49: PPP1R16B; NbExp=3; IntAct=EBI-517086, EBI-10293968;
CC       O43464; Q6ZMI0-5: PPP1R21; NbExp=3; IntAct=EBI-517086, EBI-25835994;
CC       O43464; P17980: PSMC3; NbExp=3; IntAct=EBI-517086, EBI-359720;
CC       O43464; P57052: RBM11; NbExp=3; IntAct=EBI-517086, EBI-741332;
CC       O43464; Q8WVD3: RNF138; NbExp=3; IntAct=EBI-517086, EBI-749039;
CC       O43464; Q96D59: RNF183; NbExp=3; IntAct=EBI-517086, EBI-743938;
CC       O43464; Q15287: RNPS1; NbExp=2; IntAct=EBI-517086, EBI-395959;
CC       O43464; Q96GQ5: RUSF1; NbExp=3; IntAct=EBI-517086, EBI-8636004;
CC       O43464; Q8N488: RYBP; NbExp=3; IntAct=EBI-517086, EBI-752324;
CC       O43464; Q8N6K7-2: SAMD3; NbExp=3; IntAct=EBI-517086, EBI-11528848;
CC       O43464; Q9NR46: SH3GLB2; NbExp=3; IntAct=EBI-517086, EBI-749607;
CC       O43464; Q96GM5: SMARCD1; NbExp=3; IntAct=EBI-517086, EBI-358489;
CC       O43464; Q16637-3: SMN2; NbExp=3; IntAct=EBI-517086, EBI-395447;
CC       O43464; Q8WXH5: SOCS4; NbExp=3; IntAct=EBI-517086, EBI-3942425;
CC       O43464; Q5VWN6: TASOR2; NbExp=3; IntAct=EBI-517086, EBI-745958;
CC       O43464; Q86WV5: TEN1; NbExp=3; IntAct=EBI-517086, EBI-2562799;
CC       O43464; O95150: TNFSF15; NbExp=3; IntAct=EBI-517086, EBI-16355546;
CC       O43464; Q6DKK2: TTC19; NbExp=4; IntAct=EBI-517086, EBI-948354;
CC       O43464; Q495M9: USH1G; NbExp=3; IntAct=EBI-517086, EBI-8601749;
CC       O43464; O75604-3: USP2; NbExp=3; IntAct=EBI-517086, EBI-10696113;
CC       O43464; Q8NEZ2: VPS37A; NbExp=3; IntAct=EBI-517086, EBI-2850578;
CC       O43464; Q15007-2: WTAP; NbExp=3; IntAct=EBI-517086, EBI-25840023;
CC       O43464; O00308: WWP2; NbExp=3; IntAct=EBI-517086, EBI-743923;
CC       O43464; P98170: XIAP; NbExp=23; IntAct=EBI-517086, EBI-517127;
CC       O43464; P24278: ZBTB25; NbExp=3; IntAct=EBI-517086, EBI-739899;
CC       O43464; Q9UNY5: ZNF232; NbExp=3; IntAct=EBI-517086, EBI-749023;
CC       O43464; Q8N0Y2-2: ZNF444; NbExp=3; IntAct=EBI-517086, EBI-12010736;
CC       O43464; O60304: ZNF500; NbExp=3; IntAct=EBI-517086, EBI-18234077;
CC       O43464; O15535: ZSCAN9; NbExp=3; IntAct=EBI-517086, EBI-751531;
CC       O43464; Q86V28; NbExp=3; IntAct=EBI-517086, EBI-10259496;
CC       O43464; P02666: CSN2; Xeno; NbExp=7; IntAct=EBI-517086, EBI-5260183;
CC       O43464; Q60855: Ripk1; Xeno; NbExp=2; IntAct=EBI-517086, EBI-529119;
CC       PRO_0000026946; P02666: CSN2; Xeno; NbExp=2; IntAct=EBI-5271862, EBI-5260183;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion intermembrane space. Mitochondrion
CC       membrane {ECO:0000305}; Single-pass membrane protein {ECO:0000305}.
CC       Note=Predominantly present in the intermembrane space. Released into
CC       the cytosol following apoptotic stimuli, such as UV treatment, and
CC       stimulation of mitochondria with caspase-8 truncated BID/tBID.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Endoplasmic reticulum
CC       {ECO:0000269|PubMed:10644717}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=13B;
CC         IsoId=O43464-1; Sequence=Displayed;
CC       Name=2; Synonyms=D-Omi;
CC         IsoId=O43464-2; Sequence=VSP_005359, VSP_005361;
CC       Name=3; Synonyms=p7;
CC         IsoId=O43464-3; Sequence=VSP_005360, VSP_005361;
CC       Name=4; Synonyms=p4;
CC         IsoId=O43464-4; Sequence=VSP_005362;
CC   -!- TISSUE SPECIFICITY: [Isoform 1]: Ubiquitously expressed.
CC       {ECO:0000269|PubMed:10644717}.
CC   -!- DOMAIN: The mature N-terminus is involved in the interaction with XIAP.
CC   -!- DOMAIN: The PDZ domain mediates interaction with MXI2.
CC   -!- PTM: Ubiquitinated by BIRC6; this activity is inhibited by DIABLO/SMAC.
CC       {ECO:0000269|PubMed:36758104, ECO:0000269|PubMed:36758105}.
CC   -!- PTM: Autoproteolytically activated. {ECO:0000269|PubMed:10873535}.
CC   -!- DISEASE: 3-methylglutaconic aciduria 8 (MGCA8) [MIM:617248]: An
CC       autosomal recessive inborn error of metabolism resulting in early
CC       death. Clinical features include extreme hypertonia observed at birth,
CC       alternating with hypotonia, subsequent appearance of extrapyramidal
CC       symptoms, lack of psychomotor development, microcephaly, and
CC       intractable seizures. Patients show lactic acidemia, 3-methylglutaconic
CC       aciduria, intermittent neutropenia, and progressive brain atrophy.
CC       {ECO:0000269|PubMed:27208207, ECO:0000269|PubMed:27696117}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Parkinson disease 13 (PARK13) [MIM:610297]: A complex
CC       neurodegenerative disorder characterized by bradykinesia, resting
CC       tremor, muscular rigidity and postural instability, as well as by a
CC       clinically significant response to treatment with levodopa. The
CC       pathology involves the loss of dopaminergic neurons in the substantia
CC       nigra and the presence of Lewy bodies (intraneuronal accumulations of
CC       aggregated proteins), in surviving neurons in various areas of the
CC       brain. {ECO:0000269|PubMed:15961413, ECO:0000269|PubMed:18401856}.
CC       Note=Disease susceptibility is associated with variants affecting the
CC       gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the peptidase S1C family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/41879/HTRA2";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF020760; AAB94569.2; -; mRNA.
DR   EMBL; AF141305; AAF66596.1; -; mRNA.
DR   EMBL; AF141306; AAF66597.1; -; mRNA.
DR   EMBL; AF141307; AAF66598.1; -; mRNA.
DR   EMBL; AF184911; AAG13126.1; -; mRNA.
DR   EMBL; AC006544; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000096; AAH00096.1; -; mRNA.
DR   CCDS; CCDS1951.1; -. [O43464-1]
DR   CCDS; CCDS1952.1; -. [O43464-2]
DR   CCDS; CCDS92785.1; -. [O43464-3]
DR   RefSeq; NP_001308656.1; NM_001321727.1. [O43464-3]
DR   RefSeq; NP_037379.1; NM_013247.5. [O43464-1]
DR   RefSeq; NP_659540.1; NM_145074.2. [O43464-2]
DR   PDB; 1LCY; X-ray; 2.00 A; A=134-458.
DR   PDB; 2PZD; X-ray; 2.75 A; A/B=359-458.
DR   PDB; 5FHT; X-ray; 1.95 A; A=134-458.
DR   PDB; 5M3N; X-ray; 1.65 A; A=134-458.
DR   PDB; 5M3O; X-ray; 1.70 A; A=134-458.
DR   PDB; 5TNY; X-ray; 1.70 A; A=134-458.
DR   PDB; 5TNZ; X-ray; 1.75 A; A=134-458.
DR   PDB; 5TO0; X-ray; 1.90 A; A=134-458.
DR   PDB; 5TO1; X-ray; 1.69 A; A=134-458.
DR   PDB; 5WYN; X-ray; 2.05 A; A=134-458.
DR   PDB; 7VGE; X-ray; 4.00 A; A/B/C=140-342, D/F=140-341, E=140-340.
DR   PDB; 8AUK; EM; 6.20 A; C/D/E=134-458.
DR   PDB; 8E2K; EM; 3.21 A; X/Y/Z=134-458.
DR   PDBsum; 1LCY; -.
DR   PDBsum; 2PZD; -.
DR   PDBsum; 5FHT; -.
DR   PDBsum; 5M3N; -.
DR   PDBsum; 5M3O; -.
DR   PDBsum; 5TNY; -.
DR   PDBsum; 5TNZ; -.
DR   PDBsum; 5TO0; -.
DR   PDBsum; 5TO1; -.
DR   PDBsum; 5WYN; -.
DR   PDBsum; 7VGE; -.
DR   PDBsum; 8AUK; -.
DR   PDBsum; 8E2K; -.
DR   AlphaFoldDB; O43464; -.
DR   EMDB; EMD-15672; -.
DR   EMDB; EMD-27841; -.
DR   SASBDB; O43464; -.
DR   SMR; O43464; -.
DR   BioGRID; 118165; 304.
DR   CORUM; O43464; -.
DR   ELM; O43464; -.
DR   FunCoup; O43464; 1709.
DR   IntAct; O43464; 313.
DR   MINT; O43464; -.
DR   STRING; 9606.ENSP00000258080; -.
DR   BindingDB; O43464; -.
DR   ChEMBL; CHEMBL4523137; -.
DR   MEROPS; S01.278; -.
DR   MoonDB; O43464; Predicted.
DR   TCDB; 8.A.217.1.1; the apoptosis cell death regulator (acdr) family.
DR   iPTMnet; O43464; -.
DR   PhosphoSitePlus; O43464; -.
DR   BioMuta; HTRA2; -.
DR   OGP; O43464; -.
DR   jPOST; O43464; -.
DR   MassIVE; O43464; -.
DR   PaxDb; 9606-ENSP00000258080; -.
DR   PeptideAtlas; O43464; -.
DR   ProteomicsDB; 48958; -. [O43464-1]
DR   ProteomicsDB; 48959; -. [O43464-2]
DR   ProteomicsDB; 48960; -. [O43464-3]
DR   ProteomicsDB; 48961; -. [O43464-4]
DR   Pumba; O43464; -.
DR   TopDownProteomics; O43464-2; -. [O43464-2]
DR   ABCD; O43464; 1 sequenced antibody.
DR   Antibodypedia; 3554; 772 antibodies from 43 providers.
DR   DNASU; 27429; -.
DR   Ensembl; ENST00000258080.8; ENSP00000258080.3; ENSG00000115317.14. [O43464-1]
DR   Ensembl; ENST00000352222.7; ENSP00000312893.3; ENSG00000115317.14. [O43464-2]
DR   Ensembl; ENST00000437202.2; ENSP00000399166.2; ENSG00000115317.14. [O43464-3]
DR   GeneID; 27429; -.
DR   KEGG; hsa:27429; -.
DR   MANE-Select; ENST00000258080.8; ENSP00000258080.3; NM_013247.5; NP_037379.1.
DR   UCSC; uc002smi.2; human. [O43464-1]
DR   AGR; HGNC:14348; -.
DR   ClinPGx; PA33836; -.
DR   CTD; 27429; -.
DR   DisGeNET; 27429; -.
DR   GeneCards; HTRA2; -.
DR   HGNC; HGNC:14348; HTRA2.
DR   HPA; ENSG00000115317; Low tissue specificity.
DR   MalaCards; HTRA2; -.
DR   MIM; 168600; phenotype.
DR   MIM; 606441; gene.
DR   MIM; 610297; phenotype.
DR   MIM; 617248; phenotype.
DR   OpenTargets; ENSG00000115317; -.
DR   Orphanet; 505208; 3-methylglutaconic aciduria type 8.
DR   Orphanet; 2828; Young-onset Parkinson disease.
DR   VEuPathDB; HostDB:ENSG00000115317; -.
DR   eggNOG; KOG1320; Eukaryota.
DR   GeneTree; ENSGT00940000155108; -.
DR   HOGENOM; CLU_020120_6_0_1; -.
DR   InParanoid; O43464; -.
DR   OMA; MDNYRDE; -.
DR   OrthoDB; 4217619at2759; -.
DR   PAN-GO; O43464; 5 GO annotations based on evolutionary models.
DR   PhylomeDB; O43464; -.
DR   BRENDA; 3.4.21.108; 2681.
DR   PathwayCommons; O43464; -.
DR   Reactome; R-HSA-9837999; Mitochondrial protein degradation.
DR   Reactome; R-HSA-9841251; Mitochondrial unfolded protein response (UPRmt).
DR   SignaLink; O43464; -.
DR   SIGNOR; O43464; -.
DR   Agora; ENSG00000115317; -.
DR   BioGRID-ORCS; 27429; 97 hits in 1167 CRISPR screens.
DR   ChiTaRS; HTRA2; human.
DR   EvolutionaryTrace; O43464; -.
DR   GeneWiki; HtrA_serine_peptidase_2; -.
DR   GenomeRNAi; 27429; -.
DR   Pharos; O43464; Tbio.
DR   PRO; PR:O43464; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; O43464; protein.
DR   Bgee; ENSG00000115317; Expressed in cortical plate and 199 other cell types or tissues.
DR   ExpressionAtlas; O43464; baseline and differential.
DR   GO; GO:0035631; C:CD40 receptor complex; ISS:BHF-UCL.
DR   GO; GO:0000785; C:chromatin; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0005856; C:cytoskeleton; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; NAS:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005758; C:mitochondrial intermembrane space; IDA:MGI.
DR   GO; GO:0031966; C:mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:1905370; C:serine-type endopeptidase complex; IMP:CAFA.
DR   GO; GO:0042802; F:identical protein binding; IPI:CAFA.
DR   GO; GO:0008233; F:peptidase activity; IDA:UniProtKB.
DR   GO; GO:0030291; F:protein serine/threonine kinase inhibitor activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0008236; F:serine-type peptidase activity; IDA:UniProtKB.
DR   GO; GO:1990948; F:ubiquitin ligase inhibitor activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0051082; F:unfolded protein binding; NAS:UniProtKB.
DR   GO; GO:0007628; P:adult walking behavior; IEA:Ensembl.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IMP:UniProtKB.
DR   GO; GO:0034605; P:cellular response to heat; IDA:UniProtKB.
DR   GO; GO:0035458; P:cellular response to interferon-beta; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006672; P:ceramide metabolic process; IEA:Ensembl.
DR   GO; GO:0097194; P:execution phase of apoptosis; TAS:UniProtKB.
DR   GO; GO:0030900; P:forebrain development; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0035694; P:mitochondrial protein catabolic process; TAS:Reactome.
DR   GO; GO:0007005; P:mitochondrion organization; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0045786; P:negative regulation of cell cycle; TAS:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; TAS:ParkinsonsUK-UCL.
DR   GO; GO:1902176; P:negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway; NAS:ParkinsonsUK-UCL.
DR   GO; GO:1905090; P:negative regulation of type 2 mitophagy; IEA:Ensembl.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0048666; P:neuron development; IEA:Ensembl.
DR   GO; GO:0019742; P:pentacyclic triterpenoid metabolic process; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IDA:ParkinsonsUK-UCL.
DR   GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IMP:UniProtKB.
DR   GO; GO:1903955; P:positive regulation of protein targeting to mitochondrion; HMP:ParkinsonsUK-UCL.
DR   GO; GO:0012501; P:programmed cell death; IBA:GO_Central.
DR   GO; GO:0016540; P:protein autoprocessing; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0030163; P:protein catabolic process; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006508; P:proteolysis; IMP:UniProtKB.
DR   GO; GO:1903146; P:regulation of autophagy of mitochondrion; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0009635; P:response to herbicide; IEA:Ensembl.
DR   CDD; cd06785; cpPDZ_HtrA-like; 1.
DR   DisProt; DP00315; -.
DR   FunFam; 2.40.10.120:FF:000004; Serine protease HTRA2, mitochondrial; 1.
DR   FunFam; 2.30.42.10:FF:000145; serine protease HTRA2, mitochondrial; 1.
DR   Gene3D; 2.30.42.10; -; 1.
DR   Gene3D; 2.40.10.120; -; 1.
DR   InterPro; IPR001478; PDZ.
DR   InterPro; IPR041489; PDZ_6.
DR   InterPro; IPR036034; PDZ_sf.
DR   InterPro; IPR009003; Peptidase_S1_PA.
DR   InterPro; IPR001940; Peptidase_S1C.
DR   PANTHER; PTHR22939; SERINE PROTEASE FAMILY S1C HTRA-RELATED; 1.
DR   PANTHER; PTHR22939:SF127; SERINE PROTEASE HTRA2, MITOCHONDRIAL; 1.
DR   Pfam; PF17820; PDZ_6; 1.
DR   Pfam; PF13365; Trypsin_2; 1.
DR   PRINTS; PR00834; PROTEASES2C.
DR   SMART; SM00228; PDZ; 1.
DR   SUPFAM; SSF50156; PDZ domain-like; 1.
DR   SUPFAM; SSF50494; Trypsin-like serine proteases; 1.
DR   PROSITE; PS50106; PDZ; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; Autocatalytic cleavage;
KW   Direct protein sequencing; Disease variant; Endoplasmic reticulum;
KW   Epilepsy; Hydrolase; Membrane; Mitochondrion; Neurodegeneration;
KW   Parkinson disease; Parkinsonism; Protease; Proteomics identification;
KW   Reference proteome; Serine protease; Transit peptide; Transmembrane;
KW   Transmembrane helix; Ubl conjugation; Zymogen.
FT   TRANSIT         1..31
FT                   /note="Mitochondrion"
FT   PROPEP          32..133
FT                   /evidence="ECO:0000269|PubMed:11583623"
FT                   /id="PRO_0000026945"
FT   CHAIN           134..458
FT                   /note="Serine protease HTRA2, mitochondrial"
FT                   /id="PRO_0000026946"
FT   TRANSMEM        105..125
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          364..445
FT                   /note="PDZ"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00143"
FT   REGION          166..342
FT                   /note="Serine protease"
FT   MOTIF           134..137
FT                   /note="IAP-binding motif"
FT   ACT_SITE        198
FT                   /note="Charge relay system"
FT                   /evidence="ECO:0000269|PubMed:11967569"
FT   ACT_SITE        228
FT                   /note="Charge relay system"
FT                   /evidence="ECO:0000269|PubMed:11967569"
FT   ACT_SITE        306
FT                   /note="Charge relay system"
FT                   /evidence="ECO:0000269|PubMed:11967569"
FT   VAR_SEQ         238..302
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10995577"
FT                   /id="VSP_005359"
FT   VAR_SEQ         313
FT                   /note="L -> LARELGAVSLQ (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:10971580"
FT                   /id="VSP_005360"
FT   VAR_SEQ         314..458
FT                   /note="DGEVIGVNTMKVTAGISFAIPSDRLREFLHRGEKKNSSSGISGSQRRYIGVM
FT                   MLTLSPSILAELQLREPSFPDVQHGVLIHKVILGSPAHRAGLRPGDVILAIGEQMVQNA
FT                   EDVYEAVRTQSQLAVQIRRGRETLTLYVTPEVTE -> VSETSFLPRIPAPGQCGKGRF
FT                   PLIQGCLVKFLSSSLLAISQYPTRSPQHLLVLLFGCPHPLLFV (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:10971580"
FT                   /id="VSP_005362"
FT   VAR_SEQ         372..403
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:10971580,
FT                   ECO:0000303|PubMed:10995577"
FT                   /id="VSP_005361"
FT   VARIANT         12
FT                   /note="W -> C (in dbSNP:rs775840965)"
FT                   /evidence="ECO:0000269|PubMed:18364387"
FT                   /id="VAR_076967"
FT   VARIANT         72
FT                   /note="L -> P (in dbSNP:rs150047108)"
FT                   /evidence="ECO:0000269|PubMed:18401856"
FT                   /id="VAR_046134"
FT   VARIANT         128
FT                   /note="P -> L (in dbSNP:rs757704467)"
FT                   /evidence="ECO:0000269|PubMed:18364387"
FT                   /id="VAR_076968"
FT   VARIANT         141
FT                   /note="A -> S (may be a risk factor for Parkinson disease;
FT                   reduced protease activity; dbSNP:rs72470544)"
FT                   /evidence="ECO:0000269|PubMed:15961413,
FT                   ECO:0000269|PubMed:18364387, ECO:0000269|PubMed:18401856"
FT                   /id="VAR_027349"
FT   VARIANT         227
FT                   /note="A -> S (in dbSNP:rs375322953)"
FT                   /evidence="ECO:0000269|PubMed:18364387"
FT                   /id="VAR_076969"
FT   VARIANT         243..244
FT                   /note="LP -> PS (in MGCA8; loss of protein expression;
FT                   dbSNP:rs1057519082)"
FT                   /evidence="ECO:0000269|PubMed:27696117"
FT                   /id="VAR_077960"
FT   VARIANT         399
FT                   /note="G -> S (may be a risk factor for Parkinson disease;
FT                   reduced protease activity; dbSNP:rs72470545)"
FT                   /evidence="ECO:0000269|PubMed:15961413,
FT                   ECO:0000269|PubMed:18364387, ECO:0000269|PubMed:25422467,
FT                   ECO:0000269|PubMed:27535533"
FT                   /id="VAR_027350"
FT   VARIANT         404
FT                   /note="R -> Q (in MGCA8; may lead to skipping of exon 7 and
FT                   the resultant protein may be truncated; loss of protein
FT                   expression in patient cells homozygous for the mutation;
FT                   dbSNP:rs767006508)"
FT                   /evidence="ECO:0000269|PubMed:27208207"
FT                   /id="VAR_077961"
FT   VARIANT         404
FT                   /note="R -> W (in PARK13; dbSNP:rs1380794702)"
FT                   /evidence="ECO:0000269|PubMed:18401856"
FT                   /id="VAR_046135"
FT   MUTAGEN         134
FT                   /note="A->M: Loss of interaction with XIAP. Loss of
FT                   inhibition of XIAP activity."
FT                   /evidence="ECO:0000269|PubMed:11583623"
FT   MUTAGEN         306
FT                   /note="S->A: Loss of protease activity."
FT                   /evidence="ECO:0000269|PubMed:10644717"
FT   HELIX           143..147
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   HELIX           149..157
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   HELIX           158..160
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   STRAND          161..170
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   TURN            171..174
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   STRAND          175..188
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   TURN            189..191
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   STRAND          192..195
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   HELIX           198..200
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   STRAND          204..209
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   STRAND          211..213
FT                   /evidence="ECO:0007829|PDB:5TO0"
FT   STRAND          215..224
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   TURN            225..228
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   STRAND          229..233
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   HELIX           248..250
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   STRAND          256..259
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   STRAND          265..268
FT                   /evidence="ECO:0007829|PDB:5FHT"
FT   STRAND          271..275
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   STRAND          295..299
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   TURN            303..307
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   STRAND          308..311
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   STRAND          317..326
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   STRAND          329..334
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   HELIX           335..342
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   STRAND          359..361
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   STRAND          364..368
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   HELIX           371..380
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   STRAND          382..384
FT                   /evidence="ECO:0007829|PDB:5WYN"
FT   STRAND          391..396
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   HELIX           401..405
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   STRAND          412..416
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   HELIX           424..433
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   STRAND          435..443
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   STRAND          446..452
FT                   /evidence="ECO:0007829|PDB:5M3N"
FT   STRAND          455..457
FT                   /evidence="ECO:0007829|PDB:5M3N"
SQ   SEQUENCE   458 AA;  48841 MW;  CEA955A7D0DD8C0D CRC64;
     MAAPRAGRGA GWSLRAWRAL GGIRWGRRPR LTPDLRALLT SGTSDPRARV TYGTPSLWAR
     LSVGVTEPRA CLTSGTPGPR AQLTAVTPDT RTREASENSG TRSRAWLAVA LGAGGAVLLL
     LWGGGRGPPA VLAAVPSPPP ASPRSQYNFI ADVVEKTAPA VVYIEILDRH PFLGREVPIS
     NGSGFVVAAD GLIVTNAHVV ADRRRVRVRL LSGDTYEAVV TAVDPVADIA TLRIQTKEPL
     PTLPLGRSAD VRQGEFVVAM GSPFALQNTI TSGIVSSAQR PARDLGLPQT NVEYIQTDAA
     IDFGNSGGPL VNLDGEVIGV NTMKVTAGIS FAIPSDRLRE FLHRGEKKNS SSGISGSQRR
     YIGVMMLTLS PSILAELQLR EPSFPDVQHG VLIHKVILGS PAHRAGLRPG DVILAIGEQM
     VQNAEDVYEA VRTQSQLAVQ IRRGRETLTL YVTPEVTE
//
